Condition: Small Cell Lung Cancer Extensive Stage · Sponsor: Genprex, Inc.
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
This description comes directly from the study's public registry record.
Sr Director, Clinical Operations · 1-877-774-GNPX · kcombs@genprex.com
Chief Medical Officer · 1-877-774-GNPX · mberger@genprex.com
Always discuss trial participation with your own doctor first.
| Rocky Mountain Cancer Centers, LLP | Lone Tree, Colorado, United States | Recruiting |
| Washington University School of Medicine - Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Recruiting |
| Oncology_Hematology Care Clinical Trials, LLC | Cincinnati, Ohio, United States | Recruiting |
| Oncology_Hematology Care Clinical Trials, LLC | Cincinnati, Ohio, United States | Recruiting |
| Oncology_Hematology Care Clinical Trials, LLC | Cincinnati, Ohio, United States | Recruiting |
| Oncology_Hematology Care Clinical Trials, LLC | Cincinnati, Ohio, United States | Recruiting |
| Oncology_Hematology Care Clinical Trials, LLC | Fairfield, Ohio, United States | Recruiting |
| Willamette Valley Cancer Institute (Oregon) | Eugene, Oregon, United States | Recruiting |
| Northwest Cancer Specialists, P.C. | Portland, Oregon, United States | Recruiting |
| Providence Cancer Institute | Portland, Oregon, United States | Recruiting |
| Northwest Cancer Specialists, P.C. | Portland, Oregon, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05703971